Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA
暂无分享,去创建一个
Mark E. Davis | J. Heidel | D. Kornbrust | R. Zeidan | Jeremy D Heidel | Zhongping Yu | Joanna Yi-Ching Liu | Shyam M Rele | Yongchao Liang | Ryan K Zeidan | Douglas J Kornbrust | Mark E Davis | Zhongping Yu | S. Rele | J. Liu | Yongchao Liang
[1] R. Misra,et al. Biomaterials , 2008 .
[2] Jianjun Cheng,et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles , 2004, Cancer biology & therapy.
[3] A. Söling,et al. Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine. , 2005, Current opinion in molecular therapeutics.
[4] C. Taylor,et al. Preliminary clinical study of transferrin-adriamycin conjugate for drug delivery to acute leukemia patients. , 1990, Molecular biotherapy.
[5] Yong-mei Song,et al. Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro , 2006, Nature Biotechnology.
[6] A. Lee,et al. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[7] A. Dritschilo,et al. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] Yutaka Ikeda,et al. Ligand-Targeted Delivery of Therapeutic siRNA , 2006, Pharmaceutical Research.
[9] Mark E. Davis,et al. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging , 2006, Nucleic acids research.
[10] S. Kawakami,et al. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. , 2007, Biomaterials.
[11] Matthias John,et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.
[12] M. Manoharan,et al. RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.
[13] T. Ishida,et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[14] B. Polisky,et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication , 2005, Hepatology.
[15] M McCarthy,et al. Hepatology , 1999, Rapid Medicine.
[16] R. Elliott,et al. Antineoplastic drugs that interfere with iron metabolism in cancer cells. , 1997, Advances in enzyme regulation.
[17] Theresa A. Storm,et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.
[18] Judy Lieberman,et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.
[19] R. Rosenfeld. Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[20] M. Hope,et al. Immunogenicity and Rapid Blood Clearance of Liposomes Containing Polyethylene Glycol-Lipid Conjugates and Nucleic Acid , 2005, Journal of Pharmacology and Experimental Therapeutics.
[21] Mark J. Reasor,et al. Drug-Induced Phospholipidosis: Are There Functional Consequences? , 2001, Experimental biology and medicine.
[22] Yong Wang,et al. Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.
[23] F M Muggia,et al. ROLE OF COMPLEMENT ACTIVATION IN HYPERSENSITIVITY REACTIONS TO DOXIL AND HYNIC PEG LIPOSOMES: EXPERIMENTAL AND CLINICAL STUDIES , 2002, Journal of liposome research.
[24] N. Zhong,et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque , 2005, Nature Medicine.
[25] Mark E. Davis,et al. Imidazole groups on a linear, cyclodextrin-containing polycation produce enhanced gene delivery via multiple processes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[26] Matthias John,et al. RNAi-mediated gene silencing in non-human primates , 2006, Nature.
[27] Rajan P Kulkarni,et al. Single cell kinetics of intracellular, nonviral, nucleic acid delivery vehicle acidification and trafficking. , 2005, Bioconjugate chemistry.
[28] Mark E. Davis,et al. Lack of interferon response in animals to naked siRNAs , 2004, Nature Biotechnology.
[29] Mark E. Davis,et al. Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo , 2007, Clinical Cancer Research.
[30] A. Judge,et al. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[31] Keith Bowman,et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.
[32] D. Sørensen,et al. Cationic liposome-mediated delivery of siRNAs in adult mice. , 2003, Biochemical and biophysical research communications.
[33] A. Levin,et al. Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. , 2002, Analytical biochemistry.
[34] A. Judge,et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.
[35] F. Colland,et al. Combination of active and inactive siRNA targeting the mitotic kinesin Eg5 impairs silencing efficiency in several cancer cell lines. , 2006, Oligonucleotides.
[36] Celia Arnaud. DELIVERING RNA INTERFERENCE: Developing siRNA THERAPEUTICS depends on synthetic delivery systems , 2006 .
[37] Mark E. Davis,et al. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. , 2007, Bioconjugate chemistry.
[38] M. Sioud. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. , 2005, Journal of molecular biology.
[39] M. Bodó,et al. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. , 2000, American journal of physiology. Heart and circulatory physiology.
[40] Mark E. Davis,et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. , 2005, Cancer research.
[41] Marek Langner,et al. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. , 2005, Cellular & molecular biology letters.
[42] D. Mason,et al. Transferrin receptors in human tissues: their distribution and possible clinical relevance. , 1983, Journal of clinical pathology.
[43] M. Pangburn,et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. , 1997, The Journal of pharmacology and experimental therapeutics.
[44] Andrew D. Ellington,et al. Aptamer mediated siRNA delivery , 2006, Nucleic acids research.